Recent Updates
Recently added Catalysts
WVE Positive Sentiment Score: 70/100

Wave Life Sciences Second Quarter 2024 Financial Results Scheduled for August 8, 2024

Key Takeaway: Wave Life Sciences Ltd. will host a live webcast and conference call on August 8, 2024, at 8:30 a.m. ET to discuss its second quarter 2024 financial results and provide business updates. Participants can access the call through the company's investor events webpage. Wave Life Sciences is focused on advancing RNA medicines and has a diverse pipeline targeting various diseases.

Market Sentiment Analysis

POSITIVE FACTORS

  • Upcoming financial results announce ongoing transparency
  • Wave Life Sciences highlights strong focus on RNA medicines
  • Provides diverse pipeline targeting significant disorders

Full Press Release Details

CAMBRIDGE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, August 8, 2024, to review the company’s second quarter 2024 financial results and provide business updates.
The webcast and conference call may be accessed by visiting “Investor Events” on the investors section of the Wave Life Sciences website: ir.wavelifesciences.com/events-publications/events.
Analysts planning to participate during the Q&A portion of the live call can join the conference call at the following audio conferencing link: available here. Once registered, participants will receive the dial-in information.
Following the live event, an archived version of the webcast will be available on the Wave Life Sciences website.
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity. Driven by the calling to “Reimagine Possible”, Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X (formerly Twitter) and LinkedIn.

Frequently Asked Questions

When will Wave Life Sciences host its financial results webcast?

Wave Life Sciences will host its webcast on August 8, 2024, at 8:30 a.m. ET.

Where can I access the Wave Life webcast?

The webcast can be accessed via the 'Investor Events' section on their website.

What is PRISM® in Wave Life Sciences?

PRISM® is Wave's RNA medicines platform that combines various modalities and innovations.

What pipeline programs does Wave Life Sciences have?

Wave has programs in Duchenne muscular dystrophy, Huntington's disease, and obesity.

How can analysts participate in the Q&A call?

Analysts can join the Q&A by registering for the conference call to receive dial-in info.

Last updated: Aug 1, 2024